The question whether the clinical response of cancer to chemotherapeutic agents can be predicted with sufficient accuracy by in vitro tests has been widely studied (Wilson & Neal, 1981; Salmon et al., 1980) . The data on ovarian cancer justify some optimism for clinical applicability (Wilson & Neal, 1981; Alberts et al., 1980) .
A point that has often been neglected and might explain the failure of in vitro sensitivity tests is the lack of correspondence between the concentrations and exposure time of drugs used in vitro and their disposition in patients. The pharmacokinetic parameter that best estimates the exposure of tissues to a drug is the area under the curve of concentration versus time (AUC) (Rowland & Tozer, 1980 (Mantovani et al., 1979) . In a few cases when a large number of lymphocytes was present, a second gradient (75% Ficoll-Hypaque in PBS layered on 100% FicollHypaque) was prepared to separate cancer cells from lymphocytes. After this step ascitic cells were resuspended in growth medium.
At this stage viability was tested by dye exclusion. The morphology of these preparations is reported in Figure 1 ; they consisted mainly of nests of cells. Preparations heavily contaminated by stromal elements were discarded. Since a parallel flow cytometry study was under way of the pattern of DNA distribution in this type of culture, it was anticipated that the number of diploid cells relative to the aneuploid population would decrease with time in our culture conditions. A rough cell count was made of these clusters without attempting to separate the single cells. Subsequent cultures could in fact be established from these nests of cells. and any attempt to disaggregate them resulted in loss of viability.
Only suspensions with >70% viable cells were then seeded at 3.5 x I05 viable cells ml -per well in multiwell tissue culture plates (Linbro-Flow Laboratories, Irvine, U.K.). Medium 199 was supplemented with 15% FCS, 2mM glutamine, 6% MEM essential aminoacid stock solution, 3% stock solution of MEM vitamins (all purchased from Flow Laboratories, Irvine, U.K.) and 20mM HEPES (Merck, Darmstadt, W. Germany).
The pH was 7.2 in air, with osmotic pressure maintained at 285 + 10 mosmol.
Drugs
Cell cultures from each patient were treated with the drugs given to the patients. Concentrations and contact times with cells were defined starting from the plasma AUC measured in patients after a similar schedule of adminstration. The kinetic data and the concentrations selected for in vitro studies are summarized in Table I .
Our problem encountered was the difficulty of using cyclophosphamide (CY) in vitro because this drug requires metabolic activation in vivo. The kinetics of activation and the rates of conversion of each metabolite to the next are still poorly defined, but it is well known that liver-inducing drugs strongly modify CY activation (Alberts & van Daalen Wetters 1976; Donelli et al., 1976; Field et al., 1972) . Since several of the metabolites are cytotoxic, we felt it was unrealistic to administer compounds that become activated in vitro at a fixed rate not comparable with in vivo activation. Even less satisfactory would have been to use one of the actual active metabolites. The problem was provisionally overcome by using another alkylating agent active in vivo, viz. L-phenyl-alanine mustard (L-PAM). The feasibility of using this agent was supported by the fact that L-PAM induces the same frequency of response in ovarian tumours as CY (Bagley et al., 1972) . CY is preferred in vivo, however, because of its lower toxicity.
In vitro treatment Cells were exposed to drugs after -72h of culture when the nests of cancer cells became well spread out and any debris could be washed out. Each drug was dissolved in fresh growth medium and left in contact with cells for the time given in Table I; In a few cases, when there was enough biopsy material, we also investigated whether the combination of drugs proposed for in vivo studies was more effective than the combined drugs in vitro. The tumour of patient C.G. (Table II) was insensitive to the combination of ADM + LPAM+cis-DDP at the concentrations and times of exposure given in Table I 
Discussion
For all 17 patients studied the degree of clinical response compared well with the extent of inhibition induced in vitro by at least one of the drugs administered. This "full agreement" has a lower confidence limit of 80% (P = 0.05) and is sufficient to demonstrate a correlation between the degree of clinical response and an effect of the drug on the cancer cells propagated in vitro.
In 4 patients the in vitro association of all the drugs administered was tested and the response again agreed with the clinical data. Thus in vitro treatment of cancer cells with drug concentrations comparable to the plasma levels attained in patients after therapeutic doses gives reliable results, though several problems have still to be resolved relating to drug metabolism and protein binding.
The efficacy of anticancer agents in ovarian cancer patients was recently studied by an in vitro clonogenic assay with a predictive accuracy of 73% for sensitivity and 100% for resistance (Alberts et al., 1981) . On primary cultures the correlation was positive in all 8 patients receiving a first course of chemotherapy, but only in 4/7 receiving a second course (Wilson & Neal, 1981) . In neither study was the cell exposure to drugs matched to the real exposure time in vivo since the clonogenic assay exposes cells to each drug for 1 h (Alberts et al., 1981) and the primary culture assay to each agent for 48 h (Wilson & Neal, 1981) . Among the drugs we tested adriamycin was certainly the least affected in terms of cell exposure time. However, pharmacokinetic measurements in plasma show that exposure to the drug for 30 min, calculated from the plasma AUC, is at 0.3ugml-1 (Piazza et al., 1980) . This may be correct if we take into account only the distribution phase, but to assess the entire effect of an adriamycin dose we must consider the 24h exposure that covers the 3 phases of plasma level decay. In this case the concentration calculated from the AUC is 0.05 ,gml-l (Benjamin et al., 1977) and is the time per concentration we used in this study.
In the case of HMM however 24 h exposure in vitro is critical not only because its decay in plasma covers a 24 h period (D'Incalci et al., 1978) but also because the in vitro cytotoxicity of this drug is timedependent (D'Incalci et al., 1980; Rutty & Abel, 1980) . No information is available on cis-DDP protein binding and its active form in plasma, so data were adapted in the light of available information (Gormley et al., 1979) . For L-PAM and 5-FU a 1 h exposure was indicated (Brox et al., 1979); MacMillan et al., 1978) . The method of assessing. the effect of drugs in vitro is based on our (Morasca et al., 1979) so that relations between the in vivo and in vitro effects of anticancer drugs could be followed during treatment.
From studies of mouse osteosarcoma (Morasca et al., 1974) , mammary carcinoma in the C3H mouse (Morasca et al., 1976) and human ovarian cancer (Morasca et al., 1980) , we concluded that not only had in vitro treatment to be matched to the real availability of drugs in vivo, but also since cells developed symptoms of toxicity over time, the most reasonable approach was to evaluate an endpoint of a well-matched interval after treatment. For morphological scoring this was 120h (Morasca et al., 1980) . However, morphological scoring as performed previously was extremely time-consuming so we tried other methods. Incorporation of [3H]-dT after 72 h recovery was used in parallel with morphological scoring in a small group of ovarian cancer patients to compare the effects of different times of exposure of cells to drugs (Morasca et al., 1979) . Since the findings overlapped, we adopted
[3H]-dT incorporation as a marker of viability. This approach has already been used by other groups as reviewed by Von Hoff & Weisenthal (1980) and its limitations did not apparently affect our data, probably because we did not test the acute effect of treatment but the delayed effect after 72 h recovery.
Though the data presented here are in full correlation, it must be borne in mind that there can be no general extrapolation to other tumours or drugs. Ovarian cancer grows easily in culture and in aneuploid tumours the cytofluorographic peak of the diploid population decreases in time in proportion to the aneuploid population (unpublished data). This may not be the case for other tumours. In terms of drug concentrations to be used we have already mentioned our limited knowledge of free and protein-bound cis-DDP. For other drugs, the 72 h recovery we used may not be the optimal interval for evaluating [3H]-dT uptake.
In addition the conditions for performing this kind of experiment are closely dependent upon the amount of tumour tissue available and of cancer cells present in the sample (many ascitic fluids contain only enough cells for diagnosis). Thus, our experience does not necessarily imply that this is the best method of predicting response to chemotherapy. It does, however, exploit human ovarian cancer cells from real clinical situations of sensitivity or resistance, for the study of drug associations, new drugs, mechanisms of action, and development of resistance in a morphologically and biochemically favourable tissue culture system. This work was supported by CNR Contract "Controllo della Crescita Neoplastica" No. 81.01403.96. 
